Supriya D Mehta1, Stephen Moses, Kawango Agot, Elijah Odoyo-June, Hong Li, Ian Maclean, Donald Hedeker, Robert C Bailey. 1. aDivision of Epidemiology and Biostatistics, University of Illinois at Chicago School of Public Health, Chicago, Illinois, USA bDepartments of Medical Microbiology, Community Health Sciences and Medicine, University of Manitoba, Winnipeg, Canada cImpact Research & Development Organization, Kisumu, Kenya dDepartment of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.
Abstract
BACKGROUND: In three randomized trials, medical male circumcision (MMC) reduced HIV acquisition in heterosexual men in sub-Saharan Africa by approximately 60%, after 21-24 months of follow-up. We estimated the 72-month efficacy of MMC against HIV among men retained in the Kisumu randomized trial, in which HIV acquisition was reduced by 60% after 24 months. METHODS:From 2002 to 2005, 2784 men aged 18-24 were enrolled and randomized 1 : 1 toimmediate circumcision or control. At trial end in December 2006, control men were offered free circumcision. Follow-up continued to September 2010. Cox proportional hazards regression incorporating stabilized inverse probability of treatment and censoring weights generated through marginal structural modeling, was used to account for potential time-varying confounding and censoring to estimate the efficacy of MMC on HIV risk. RESULTS: The cumulative 72-month HIV incidence was 7.21% [95% confidence interval (CI): 5.98-8.68%]: 4.81% among circumcised men, 11.0% among uncircumcised men. The crude hazard ratio of HIV seroconversion for circumcised vs. uncircumcised men was 0.38 [95% CI: 0.26-0.55]. In weight-adjusted Cox regression, the hazard ratio was 0.42 [95% CI: 0.26-0.66]. CONCLUSION: The efficacy of MMC was sustained at 58% at 72 months, similar to overall findings of the three trials under conditions of randomization. These findings provide an estimate of the long-term efficacy of circumcision against HIV acquisition. Our results support programmatic scale-up recommendations that are based on assumptions of sustained efficacy.
RCT Entities:
BACKGROUND: In three randomized trials, medical male circumcision (MMC) reduced HIV acquisition in heterosexual men in sub-Saharan Africa by approximately 60%, after 21-24 months of follow-up. We estimated the 72-month efficacy of MMC against HIV among men retained in the Kisumu randomized trial, in which HIV acquisition was reduced by 60% after 24 months. METHODS: From 2002 to 2005, 2784 men aged 18-24 were enrolled and randomized 1 : 1 to immediate circumcision or control. At trial end in December 2006, control men were offered free circumcision. Follow-up continued to September 2010. Cox proportional hazards regression incorporating stabilized inverse probability of treatment and censoring weights generated through marginal structural modeling, was used to account for potential time-varying confounding and censoring to estimate the efficacy of MMC on HIV risk. RESULTS: The cumulative 72-month HIV incidence was 7.21% [95% confidence interval (CI): 5.98-8.68%]: 4.81% among circumcised men, 11.0% among uncircumcised men. The crude hazard ratio of HIV seroconversion for circumcised vs. uncircumcised men was 0.38 [95% CI: 0.26-0.55]. In weight-adjusted Cox regression, the hazard ratio was 0.42 [95% CI: 0.26-0.66]. CONCLUSION: The efficacy of MMC was sustained at 58% at 72 months, similar to overall findings of the three trials under conditions of randomization. These findings provide an estimate of the long-term efficacy of circumcision against HIV acquisition. Our results support programmatic scale-up recommendations that are based on assumptions of sustained efficacy.
Authors: Supriya D Mehta; Stephen Moses; Kawango Agot; Ian Maclean; Elijah Odoyo-June; Hong Li; Robert C Bailey Journal: J Infect Dis Date: 2013-07-30 Impact factor: 5.226
Authors: Jeanne M Marrazzo; Carlos del Rio; David R Holtgrave; Myron S Cohen; Seth C Kalichman; Kenneth H Mayer; Julio S G Montaner; Darrell P Wheeler; Robert M Grant; Beatriz Grinsztejn; N Kumarasamy; Steven Shoptaw; Rochelle P Walensky; Francois Dabis; Jeremy Sugarman; Constance A Benson Journal: JAMA Date: 2014 Jul 23-30 Impact factor: 56.272
Authors: Robert L Glaubius; Greg Hood; Kerri J Penrose; Urvi M Parikh; John W Mellors; Eran Bendavid; Ume L Abbas Journal: Clin Infect Dis Date: 2016-05-18 Impact factor: 20.999